IRulya Therapeutics Inc.
IRLA · XNASCIK 1662774fmd_19E4P0V42K43F0WRQ1HK5F10N9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Jun 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 10 | 30 | 61 | 61 | 25 | 9 | 19 | 35 |
| Total operating expenses | 12 | 39 | 79 | 90 | 52 | 35 | 57 | 58 |
| Operating income | (12) | (39) | (79) | (90) | (52) | (35) | (57) | (58) |
| Interest expense | 1 | – | – | – | – | – | – | – |
| Interest and investment income | 1 | 2 | 2 | 1 | 1 | 3 | 3 | 1 |
| Other non-operating income (expense) | – | 0 | 0 | (0) | (1) | (0) | (1) | 0 |
| Income before taxes | – | (37) | (77) | (90) | (52) | (32) | (57) | (81) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | (0) | 0 | 3 |
| Net income from continuing operations | – | (37) | (77) | (90) | (52) | (31) | (57) | (84) |
| Net income | (12) | (37) | (77) | (90) | (52) | (31) | (57) | (84) |